WWOX is a tumour suppressor gene that spans the common fragile site FRA16D. Analysis of the WWOX expression pattern in normal human tissues showed the highest expression in testis, prostate, and ovary. Its altered expression has been demonstrated in different tissues and tumour types. The WWOX gene encodes a 414-amino acids protein, which is the fi rst discovered protein with a short-chain dehydrogenase/reductase (SDR) central domain and two WW domains at the NH 2 terminus. Due to its potential role in sex-steroid metabolism, using two bacterial expression systems, we have cloned WWOX fusion proteins showing oxidoreductase activity in a crude extract, defi ned a course of enzymatic reactions for selected steroid substrates, and determined related K m values. Our results show that the SDR domain of the WWOX protein has dehydrogenase activity and is reactive both in the presence of NAD + and NADP + for all examined steroid substrates. On the other hand, with the same substrates and reduced cofactors (NADH and NADPH) reduction activity was not observed.
Introduction
WWOX is a newly identifi ed tumour suppressor gene located on a long arm of chromosome 16 (16q23.3-24.1) (Bednarek et al., 2000) . This genomic area is recognized as the common fragile site FRA16D, which is the second most affected fragile site in cancer. Both genomic alterations within the WWOX gene (Paige et al., 2000 (Paige et al., , 2001 and its altered expression are frequently observed in different tissues and cancer types (Aqeilan et al., 2004a; Guler et al., 2004; Kuroki et al., 2002 Kuroki et al., , 2004 Nunez et al., 2005a; Pluciennik et al., 2006) . Interestingly, it was shown that ectopically elevated WWOX expression in cancer cell lines results in tumour growth suppression and apoptosis (Bednarek et al., 2001; Iliopoulos et al., 2007; Kuroki et al., 2004) . A recent study has shown a possible regulation of WWOX expression by promoter methylation or histone deacetylation (Iliopoulos et al., 2005 (Iliopoulos et al., , 2007 Ishii et al., 2003) . However, CpG island methylation of the WWOX gene did not display remarkable in prostate carcinomas and benign prostate hyperplasias (Bastian et al., 2007) . On the other hand, methylation analysis in pancreatic carcinogenesis demonstrated an increase in the expression of the WWOX gene after treatment with the methylation inhibitor 5-aza-2'-deoxycytidine (Kuroki et al., 2004 (Kuroki et al., , 2006 .
Analysis of the WWOX expression pattern in normal human tissues showed the highest expression in testis, prostate, and ovary, signifi cantly lower expression in other tissues (spleen, thymus, small intestine or colon), and very low expression in bulk breast tissues (Bednarek et al., 2000) .
The WWOX gene encodes a 414-amino acids protein (46 kDa) which is the fi rst discovered protein with a short-chain dehydrogenase/reductase (SDR) central domain and two WW domains at the NH 2 terminus (Bednarek et al., 2000) , and at the same time WWOX protein localization within the Golgi system requires an intact SDR domain (Bednarek et al., 2001) . WW domains are involved in protein-protein interactions, and up to now several proteins were identifi ed as candidates of WWOX partners. The WWOX protein interacts with p73 and this may result in redistribution of nuclear p73 to the cytoplasm, suppressing its transcriptional activity (Aqeilan et al., 2004b protein interacts with the Ap2-γ transcription factor involved in cell proliferation and suppresses its transactivating ability (Aqeilan et al., 2005) . WWOX associates also with the full-length ErbB-4/ tyrosine kinase receptor via its fi rst domain, thus competes with the YAP protein, affecting its transcriptional activity (Aqeilan et al., 2005) . Additionally, WWOX via its fi rst WW domain specifi cally associates with the proline-rich motif of c-Jun proto-oncogene. Phosphorylation of c-Jun caused by Mekk1 (mitogen-activated protein kinase 1) enhances the interaction of c-Jun with WWOX. It was also found that expression of WWOX attenuates the ability of Mekk1 to increase the activity of c-Jun-driven AP-1 (activating protein 1).
Furthermore, the WWOX protein activity is regulated by Ack1 (Cdc42-intracellular associated tyrosine kinase), which phosphorylates WWOX at two different sites (Tyr 33 and Tyr 287 ) resulting in two radically different outcomes (Mahajan et al., 2005) . Nunez et al. (2005a) observed a strong correlation between ER and PR with WWOX expression in breast cancer, but only the PR receptor status was associated with WWOX expression in ovarian carcinomas (Nunez et al., 2005b) . These correlations were also studied by Pluciennik et al. (2006) in breast cancer. Such fi ndings suggest that WWOX may be involved in steroid signalling/ metabolic pathways through its SDR domain. The most conserved features of SDR proteins are two domains constituting the cofactor (GXXXGXG) and substrate (YXXXK) binding sites (Jornvall et al., 1995; Kallberg et al., 2002a (Bednarek et al., 2000; Duax and Ghosh, 1997) . Moreover, based on clustering analysis of amino acid sequences of different SDR proteins, WWOX was recently classifi ed in the same cluster as 17β-hydroxysteroid dehydrogenase 3 (Kallberg et al., 2002b; Marijanovic et al., 2003) . Also Chang et al. (2005) showed that WWOX could be activated in cell culture conditions by 17β-estradiol treatment in lung epithelial cells, COS7 fi broblasts, and DU145 prostate cell line, but not in MCF7 breast cancer cell line. A strong association of WWOX expression with ER status reinforces the suggested role of this protein as an enzyme involved in sex-steroid metabolism (Nunez et al., 2005b) . More recently, Aqeilan et al. (2009) confi rmed on KO mice the role of WWOX in steroidogenesis and proper gonadal function. Its direct involvement in the steroidogenesis pathway was indicated by failure of Leidig cell formation, undectable levels of serum testosterone, reduced theca cells proliferation, and smaller follicles in ovary of KO mice, in which WWOX was absent or reduced. Moreover, they identifi ed 15 genes involved in steroidogenesis which had altered expression levels in the absence of WWOX. They also showed that the fi rst WW domain of this protein is essential for proper steroid-related gene expression and indicated the importance of this domain in the association process with regulating steroid enzymes transcription factors. These fi ndings suggest that the WWOX protein participates in sex-steroid metabolism (Aqeilan et al., 2009) .
In our study, using two bacterial expression systems, we have cloned WWOX fusion proteins showing oxidoreductase activity in a crude extract, defi ned a course of enzymatic reactions for selected steroid substrates, and determined related K m values. + , β-NADH, β-NADPH, 17β-estradiol (17β-E), estrone (E), 5α-androstane-3,17-dione (5α-A), 4-androstene-3,17-dione (4-A), progesterone (P), 5α-dihydroprogesterone-allo (5α-DHP-allo) were purchased from Sigma (St. Louis, MO, USA); testosterone (T) was bought from Fluka (Buchs, Switzerland); enzymes: BamHI, EcoRI, MssI, SmaI, CIAP (calf intestine alkaline phosphatase), T4 DNA ligase were delivered from Fermentas UAB (Vilnius, Lithuania); Tween ® 20, Nonident P-40 were taken from Calbiochem (Darmstadt, Germany); other reagents and organic solvents were obtained from Sigma and AppliChem GmbH (Darmstadt, Germany) or were of the highest quality commercially available.
Experimental

Materials
Expression and soluble fraction with WWOX fusion protein
The WWOX cDNA fragment restricted by BamHI and EcoRI enzymes was subcloned from pcDNA 3.1.A into the pET 44a(+) expression vector. Constructs with WWOX-pET vector were subsequently introduced into E. coli TOP-10 and E. coli Origami B (DE3) pLysS by chemical transformation. For analysis of the WWOX protein, Origami B (DE3) pLysS cells, containing WWOX-pET or pET 44a(+) vector, were grown in 2 x YT medium at 37 °C with 50 μg/ml ampicillin. After the absorbance at 595 nm had reached 0.4 -0.5, the cell cultures were chilled at 4 °C for 30 min. In order to induce protein expression isopropyl β-D-thiogalactopyranoside (IPTG) was added to a fi nal concentration of 0.2 mM, ethanol to the fi nal strength of about 0.2%, and cells were incubated overnight at 16 -18 °C.
The cultures were centrifuged and resulting pellets washed with PBS buffer. Pellets then were lysed in mild conditions using CelLytic B II at room temperature. Subsequently, lysates were treated with lysozyme (fi nal concentration of 120 μg/ml) for 5 min at 23 °C. Then RN-ase/DN-ase I mixture (8 μg/ml) and sarkosyl (0.003%) were added (incubation for 20 min at 23 °C). Finally, an equal volume of stabilizing buffer [40 mM Tris-HCl, pH 8.0, 0.6 M NaCl, 10 mM 2-mercaptoethanol, 10% (v/v) glycerol, 0.4% Tween 20, and 0.4% Nonident P-40] was supplemented (incubation) for 30 min at 23 °C. Supernatants, containing a soluble fraction of NUS protein or NUS-WWOX fusion protein, were collected for analysis (Fig. 1A) . Protein concentrations were measured according to Bradford (1976) , using bovine serum albumin as a standard.
Fusion proteins purifi cation was performed on glutathione-sepharose (Bulk GST Purifi cation Module) and TALON metal affi nity resin (with Co 2+ ) for GST-WWOX and NUS-WWOX fusion proteins, respectively (Figs. 1A, B) . As the oxidoreductase activity was lost during purifi cation, we have used a soluble fraction of a bacterial crude extract for enzyme kinetics analysis.
Initially, dehydrogenase activity was investigated using a common dehydrogenase substrate -S-indan-1-ol and NAD + . Fig. 2 shows differences between oxidoreductase activity of NUS-WWOX and NUS ( Fig. 2A) , and GST-WWOX and GST proteins (Fig. 2B) .
Enzyme assays
The dehydrogenase and reductase activities of a soluble fraction of the whole protein extract containing NUS protein or NUS-WWOX fusion protein were analysed using the following approach. All reactions were monitored at 340 nm at 25 °C to follow changes in absorbance of the nicotinamide nucleotide cofactor (ε = 6270 M -1 cm -1 ) in time. The absorbance was measured in 5-min intervals, during a 30-min incubation with or without addition of NAD(P) + or NAD(P)H. The standard reaction mixture for both dehydrogenase and reductase activity consisted of 100 mM 15 μmol NADH/NADPH, 0.24 μmol of each substrate (5α-androstane-3,17-dione, 4-androstene-3,17-dione, 17β-estradiol, estrone, 5α-dihydroprogesterone-allo, progesterone, testosterone), and 400 μg of the whole protein extract in a total volume of 1 ml. The reaction was initiated by addition of the whole protein fraction and corrected for initial changes.
The apparent K m value for the steroid substrates was determined by the steady-state kinetics method, and Lineweaver-Burk analysis was applied in order to fi nd K m and V max values for the WWOX dehydrogenase activity. Concentrations of the substrates were changed in 0.025-μmol/ml or 0.05-μmol/ml intervals ( Table I) . The reaction mixture consisted of 100 mM potassium phosphate buffer (pH 7.4), 0.75 μmol NAD + or NADP + , varying concentrations of the steroids, and 400 μg of the whole protein extract with NUS protein or NUS-WWOX fusion protein.
After incubation at 25 °C steroid dehydrogenase assays were quenched with a 0.5-ml mixture of methanol/chloroform (1:1, v/v), vortexed, and the water fraction was separated by centrifugation. The dehydrogenase activity of the recombinant WWOX protein was calculated as the difference in absorbances at 340 nm of the NUS-WWOX fusion cell extract and plain NUS cell extract. Unless otherwise noted, the kinetics values were the means of at least two or three demonstrations.
Statistical analysis
Statistical analysis of the dehydrogenase activity levels of WWOX fusion protein in the crude bacterial protein extracts was performed using Mann-Whitney test. We compared K m values for recombinant WWOX fusion protein (the difference between NUS-WWOX and NUS) with NUS Each assay was performed in relation to activity in the corresponding soluble fraction of the crude protein extract without WWOX. (A) Activities of two protein soluble fractions: "NUS-WWOX fusion protein" and "NUS protein" (Fig. 1A, lane 3 and lane 1, respectively) . (B) Activities of "GST-WWOX fusion protein" and "GST protein", both soluble fractions (Fig. 1B , lane 3 and lane 1, respectively). The curves shown are from one of two experiments, each done with a separate isolation of the soluble fractions. 
Results
NUS-WWOX and GST-WWOX fusion proteins extraction
Various variants of the purifi cation process of NUS-WWOX fusion protein were investigated. Because the oxidoreductase activity was lost in any attempt of purifi cation to near-homogeneity of WWOX fusion protein, we decided to use the soluble fraction of bacterial crude extract for our enzymatic studies.
In the second bacterial gene expression system we obtained a soluble fraction of the whole protein extract with GST-WWOX fusion protein, in which dehydrogenase activity was observed as well. The amount of the soluble GST-WWOX fusion protein was greater in the crude protein extract than in the preparations with NUS-WWOX, but its stability and the enzymatic activity varied over time. The same problem -loss of dehydrogenase activity -was observed during attempts of purifi cation to homogeneity of the GST-WWOX fusion protein from bacterial proteins (Fig. 1) .
Oxidoreductase activity of the WWOX protein
This work proves the oxidoreductase activity of the SDR domain, present in the NUS-WWOX fusion protein. Preliminary analysis of the redox reactions for various concentrations of steroid substrates, cofactors, and NUS-WWOX fusion protein in the crude protein extracts enabled us to determine conditions which were used for reactions in the presence of the steroids 5α-dihydroprogesterone-allo (5α-DHP-allo), progesterone (P), 5α-androstane-3,17-dione (5α-A), 4-androstene-3,17-dione (4-A), 17β-estradiol (17β-E), estrone (E), testosterone (T).
Because the enzymatic activity of NUS-WWOX fusion protein was studied in a crude extract of bacterial proteins, it was necessary to determine simultaneously the activities of crude protein extracts with NUS protein alone, in the presence of the same steroid substrates and cofactors. Endogenous oxidoreductase activities of whole protein extracts with NUS-WWOX fusion protein or only NUS protein without the steroid substrates for each cofactor were treated as a blank for each corresponding test.
Our results showed that the SDR domain of the WWOX protein has dehydrogenase activity and is reactive both in the presence of NAD + and NADP + for all examined steroid substrates. The reduction activities with the same seven steroid substrates and reduced cofactors (NADH or NADPH) were similar for both protein extract with NUS protein or NUS-WWOX fusion protein (results not shown), which indicates that the NUS-WWOX fusion protein has no reduction activity.
Dehydrogenase activity of SDR domain in the WWOX protein
A course of each enzymatic reaction was observed over the same period of time -30 min for all steroids (5α-DHP-allo, P, 5α-A, 4-A, 17β-E, E, T) and NAD + or NADP + as a cofactor. For reactions with NAD + the amount of steroid hormone at 0.24 μmol/ml was suffi cient or even excessive but the saturation of enzymatic proteins with the substrate occurred at different times. The oxidoreductase activity decreased dramatically when the specifi c steroid substrate was not added to the reaction mixture (Fig. 3) .
For protein fractions with NUS-WWOX fusion protein, which had dehydrogenase activity, hyperbolic curves were obtained, suggesting that there is only one site for the steroid-to-substrate bond.
The enzymatic activity of the host bacterial protein extracts varied among substrates. The activity level was relatively low with 5α-DHP-allo, E, and T (3-to 6-fold lower compared to NUS-WWOX extracts), and for the remaining studied steroid substrates (P, 17β-E, 5α-A, 4-A) the oxidation activity was at the level corresponding to the blank.
For NADP + used as cofactor, reaction kinetics was similar to NAD + (Fig. 3B) . Our results obtained for the dehydrogenase activity of the WWOX fusion protein indicate that the WWOX protein was active with all seven steroids, and velocities of enzymatic reactions were higher for NAD + than NADP + as cofactor. Subsequently K m values for the dehydrogenase activity of the WWOX protein (as NUS-WWOX fusion protein) with the examined steroid substrates and cofactors were determined (Table II) . For the given substrate, the enzymatic activity of the WWOX protein was calculated as the difference between activity of the crude protein extract with NUS-WWOX and the activity of the crude 
Discussion
WWOX is the fi rst discovered protein which contains a SDR domain and two WW proteinprotein interaction domains (Bednarek et al., 2000) . In the presented work the enzymatically active WWOX protein was obtained as a fusion protein in two bacterial expression systems. However, it appeared impossible to purify the fusion protein without loss of activity. This suggests that the WWOX protein with dehydrogenase activity is in vivo present in a cell only in liaison with other cell proteins which have to be substituted even in bacterial expression systems. In our study the WWOX protein retained its activity in the soluble fraction of a bacterial crude extract which may imply that WWOX partners are present amongst bacterial proteins.
In this experiment we proved that the SDR domain of the WWOX protein has dehydrogenase activity, and WWOX is reactive in the presence of all seven examined steroid substrates (5α-DHPallo, P, 5α-A, 4-A, 17β-E, E, T) and NAD + and NADP + as cofactors. However, the activity of all substrates was higher with NAD + . On the other hand, with the same substrates and reduced cofactors (NADH and NADPH) reduction activity was not observed.
The highest expression of WWOX in hormonedependent tissues, such as testis, prostate, and ovary, suggests its involvement in the steroid hormone metabolism. Indeed, this study confi rms that the examined steroids may be the substrates for the SDR domain of the WWOX protein. Also the lowest K m values of the WWOX protein obtained for estrone as steroid substrate suggests that the WWOX protein participates in the estrone metabolism in vivo. Moreover, the SDR domain in the WWOX protein has a specifi c amino acids sequence (Bednarek et al., 2000) that was classifi ed in the same cluster as 17β-hydroxysteroid dehydrogenase 3 (Kallberg et al., 2002b; Marijanovic et al., 2003) . Our results are consistent with those from Chang et al. (2005) who showed that WWOX could be activated in cell culture conditions by 17β-estradiol treatment in lung epithelial cells and DU145 prostate cell line. Furthermore, is has been shown that the WWOX protein is necessary for proper gonadal development and function, and its absence alters the expression level of 15 steroidogenesis-related genes (Aqeilan et al., 2009) . A correlation of ER and/or PR levels with WWOX expression was observed in breast and ovary cancers (Chang et al., 2005; Nunez et al., 2005a, b; Pluciennik et al., 2006) , and this also supports the suggested role of this protein as an enzyme of central role in sex-steroid synthesis and metabolism.
Like in tumour cells incorrect WWOX transcripts have been found (Bednarek et al., 2000; Driouch et al., 2002) , which lacked a substratebinding part of the SDR domain; it is very likely that oxidoreductase activity and its loss in WWOX protein is of great importance in cancerogenesis. Therefore, further investigations concerning WWOX and its enzymatic activity need to be conducted.
